AC Immune Beefs Up Neurodegenerative Pipeline With AFFiRiS Alpha-Synuclein Portfolio
Executive Summary
Deal Snapshot: The company is looking to expand its pipeline beyond Alzheimer’s, where it hit a speedbump in September with the failure of a tau-targeting drug.
You may also be interested in...
AC Immune Keeps Faith In Alzheimer’s Breakthrough, But Spreads Risk With Parkinson’s Bet
Interview: The Swiss biotech has endured many Alzheimer’s failures, but has been able to broaden its portfolio and income streams while the search for a breakthrough goes on.
Deal Watch: Seagen Ups Presence In HER2-Positive Cancer Field With RemeGen Deal
Lilly partners with Kumquat to discover small molecule IO drug. Kite, Appia Bio collaborate on allogeneic cell therapies. AstraZeneca and Regeneron pursue novel metabolic therapies targeting GPR75. Lexeo and Stelios merge to focus on gene therapies for rare cardiovascular indications.
Early Data From Ionis/Biogen’s BIIB080 Keeps Tau Alzheimer’s Hopes Alive
While many other approaches have failed, Ionis and Biogen hope their novel oligonucleotide can stop toxic tau tangles forming in the brain.